Welcome to Our Medtech Talk Podcast Channel
Too often we define the Medtech sector by the number of dollars raised, IPOs helped or companies sold. But the focus neglects the very foundation of the sector - the People. Join the Medtech Talk Podcast each week to hear from entrepreneurs, investors and executives who spend their days developing the tools that make sick people well and health care more efficient.
Ceribell’s rapid seizure triage product for critical care received FDA’s Breakthrough Designation with an exclusive New Technology Add-on Payment (NTAP) from CMS. Everything about the ClarityPro product—from the innovative EEG headband to the EEG recorder and physician portal has been engineered to enable quick detection and response to non-convulsive seizure in a critical care or ED setting. In this episode of the Medtech Talk podcast, host Geoff Pardo speaks with Jane Chao, CEO of Ceribell, about the path to develop an innovative new product and her personal journey as well.
Chao’s own story started with a love of numbers, a highly exclusive spot earned in a prestigious chemistry program in Beijing, a Ph.D. in biophysics, and roles at McKinsey, Novartis, and Genentech. For Ceribell’s genesis, Chao took lessons from all of those experiences—business knowledge gained at McKinsey, and a rich, interdisciplinary scientific background—to launch a new medtech business and engineer a new device to meet a critical, unmet medical need.
Jane Chao, the co-founder and CEO of Ceribell, holds a Ph.D. in biophysics from Cornell University. Before she joined Ceribell, Jane had a solid history of leadership and success in business. She launched her career as a management consultant with McKinsey & Company, and later made her move into the medical space joining Novartis as their Senior Strategy Manager. She then enjoyed a successful career at Genentech as their Principal Manager of Portfolio Management Strategy.
In 2015, Jane started Ceribell full-time as the CEO, the position she currently holds. She has built and led the Ceribell team from early concept stages to a fully commercial, FDA-cleared, clinically proven, and highly successful commercial product that is changing the standard of care for critically ill patients.
